NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) by Merck & Co. is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DELSTRIGO is a fixed-dose combination tablet containing doravirine (a non-nucleoside reverse transcriptase inhibitor), lamivudine, and tenofovir disoproxil fumarate approved by the FDA on August 30, 2018. It is indicated for the treatment of HIV-1 infection in treatment-naive and treatment-experienced adults. The product combines three antiretroviral agents with complementary mechanisms to suppress viral replication. DELSTRIGO represents a once-daily oral option in the mature HIV treatment landscape, competing within the integrase inhibitor and NNRTI-based regimen categories.
$0.0BPart D
10.6 years to LOEMechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
Started Nov 2023
18 enrolled
Hiv
Career Relevance
Currently, there are 0 open positions linked to DELSTRIGO, indicating minimal active hiring related to this product. Career opportunities for healthcare professionals would typically include brand management, field sales roles, and Medical Science Liaison positions focused on treatment-experienced and alternative-seeking patient populations. Success in marketing this product requires deep expertise in HIV treatment guidelines, understanding of prescriber switching dynamics, and ability to position DELSTRIGO against rapidly evolving preferred agent classes.
Worked on DELSTRIGO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.